SPYRE THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
SPYRE THERAPEUTICS, INC. (SYRE) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$375.00K.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$440.00K, a 153.99% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | -$163.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | -$163.00K derived: sum of 3 quarters · filed 2026-02-19 | -$1.65M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q/A · filed 2024-11-18 | -$163.00K derived: sum of 2 quarters · filed 2026-02-19 | -$1.65M derived: sum of 3 quarters · filed 2026-02-19 | -$330.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$163.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$1.65M derived: sum of 2 quarters · filed 2026-02-19 | -$330.00K derived: sum of 3 quarters · filed 2026-02-19 | -$375.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | -$1.48M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$167.00K derived: sum of 2 quarters · filed 2024-11-18 | -$212.00K 10-Q/A · filed 2024-11-18 | -$506.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.32M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $1.27M 10-Q/A · filed 2024-11-18 | $977.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$45.00K 10-Q/A · filed 2024-11-18 | -$339.00K derived: sum of 2 quarters · filed 2025-02-27 | -$149.00K derived: sum of 3 quarters · filed 2025-02-27 | -$682.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$104.00K derived: sum of 2 quarters · filed 2025-02-27 | -$637.00K derived: sum of 3 quarters · filed 2025-02-27 | -$440.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$343.00K derived: sum of 2 quarters · filed 2023-11-09 | -$146.00K 10-Q · filed 2023-11-09 | $669.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$336.00K 10-Q · filed 2023-08-11 | $479.00K derived: sum of 3 quarters · filed 2024-11-18 | $479.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $197.00K 10-Q · filed 2023-05-11 | $1.01M derived: sum of 2 quarters · filed 2024-11-18 | $1.01M derived: sum of 3 quarters · filed 2024-11-18 | -$20.49M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $815.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $815.00K derived: sum of 2 quarters · filed 2024-11-18 | -$20.68M derived: sum of 3 quarters · filed 2024-11-18 | $815.00K 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$21.50M derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $21.50M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-08 | |||
| 2018-12-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$4.28M derived: sum of 2 quarters · filed 2021-03-18 | -$3.37M derived: sum of 3 quarters · filed 2021-03-18 | -$3.08M 10-K · filed 2021-03-18 |
| 2018-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$951.00K derived: sum of 2 quarters · filed 2019-11-06 | -$656.00K 10-Q · filed 2019-11-06 | -$30.00K derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $908.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.20M 10-Q · filed 2019-08-06 | $1.83M derived: sum of 3 quarters · filed 2020-02-24 | $3.07M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $295.00K 10-Q · filed 2019-05-07 | $921.00K derived: sum of 2 quarters · filed 2020-02-24 | $2.16M derived: sum of 3 quarters · filed 2020-02-24 | $2.39M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $626.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $1.86M derived: sum of 2 quarters · filed 2020-02-24 | $2.10M derived: sum of 3 quarters · filed 2020-02-24 | $1.86M 10-K · filed 2020-02-24 |
| 2017-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.47M derived: sum of 2 quarters · filed 2018-11-08 | $1.24M 10-Q · filed 2018-11-08 | $881.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$2.00K 10-Q · filed 2018-08-09 | -$358.00K derived: sum of 3 quarters · filed 2019-03-07 | -$412.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$234.00K 10-Q · filed 2018-05-08 | -$590.00K derived: sum of 2 quarters · filed 2019-03-07 | -$644.00K derived: sum of 3 quarters · filed 2019-03-07 | -$637.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$410.00K derived: sum of 2 quarters · filed 2019-03-07 | -$403.00K derived: sum of 3 quarters · filed 2019-03-07 | -$482.00K 10-K · filed 2019-03-07 |
| 2016-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$47.00K derived: sum of 2 quarters · filed 2017-11-07 | -$126.00K 10-Q · filed 2017-11-07 | -$2.66M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$72.00K 10-Q · filed 2017-08-09 | -$2.61M derived: sum of 3 quarters · filed 2018-03-13 | -$1.80M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | -$79.00K 10-Q · filed 2017-05-09 | -$2.62M derived: sum of 2 quarters · filed 2018-03-13 | -$1.81M derived: sum of 3 quarters · filed 2018-03-13 | |
| 2015-12-31 | -$2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$1.73M derived: sum of 2 quarters · filed 2018-03-13 | $1.70M 10-K · filed 2018-03-13 | |
| 2015-09-30 | $808.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $4.24M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $3.43M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |